Details for Patent: 8,198,262
✉ Email this page to a colleague
Which drugs does patent 8,198,262 protect, and when does it expire?
Patent 8,198,262 protects POMALYST and is included in one NDA.
Protection for POMALYST has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has three hundred and six patent family members in forty countries.
Summary for Patent: 8,198,262
Title: | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Abstract: | Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. |
Inventor(s): | Zeldis; Jerome B. (Princeton, NJ) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 12/229,074 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,198,262 |
Patent Claim Types: see list of patent claims | Use; Dosage form; Delivery; |
Drugs Protected by US Patent 8,198,262
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-001 | Feb 8, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-002 | Feb 8, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-003 | Feb 8, 2013 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Bristol | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-004 | Feb 8, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,198,262
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 2105135 | ⤷ Sign Up | 1590004-6 | Sweden | ⤷ Sign Up |
European Patent Office | 2105135 | ⤷ Sign Up | C300717 | Netherlands | ⤷ Sign Up |
European Patent Office | 2105135 | ⤷ Sign Up | CA 2015 00006 | Denmark | ⤷ Sign Up |
European Patent Office | 2105135 | ⤷ Sign Up | 92642 | Luxembourg | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |